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Atorvastatin with or without an Antibody
to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth, M.D., James M. McKenney, Pharm.D., Corinne Hanotin, M.D.,
Gaelle Asset, M.Sc., and Evan A. Stein, M.D., Ph.D.

A BS T R AC T
Background

Serum proprotein convertase subtilisin/kexin 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors, increasing the degradation of LDL receptors and reducing the
rate at which LDL cholesterol is removed from the circulation. REGN727/SAR236553
(designated here as SAR236553), a fully human PCSK9 monoclonal antibody, increases the recycling of LDL receptors and reduces LDL cholesterol levels.
Methods

We performed a phase 2, multicenter, double-blind, placebo-controlled trial involving
92 patients who had LDL cholesterol levels of 100 mg per deciliter (2.6 mmol per liter)
or higher after treatment with 10 mg of atorvastatin for at least 7 weeks. Patients were
randomly assigned to receive 8 weeks of treatment with 80 mg of atorvastatin daily
plus SAR236553 once every 2 weeks, 10 mg of atorvastatin daily plus SAR236553 once
every 2 weeks, or 80 mg of atorvastatin daily plus placebo once every 2 weeks and were
followed for an additional 8 weeks after treatment.
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Results

The least-squares mean (±SE) percent reduction from baseline in LDL cholesterol was
73.2±3.5 with 80 mg of atorvastatin plus SAR236553, as compared with 17.3±3.5
with 80 mg of atorvastatin plus placebo (P<0.001) and 66.2±3.5 with 10 mg of atorvastatin plus SAR236553. All the patients who received SAR236553, as compared with
52% of those who received 80 mg of atorvastatin plus placebo, attained an LDL cholesterol level of less than 100 mg per deciliter, and at least 90% of the patients who
received SAR236553, as compared with 17% who received 80 mg of atorvastatin plus
placebo, attained LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol
per liter).
Conclusions

In a randomized trial involving patients with primary hypercholesterolemia, adding
SAR236553 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a significantly greater reduction in LDL cholesterol than that attained with 80 mg of ator
vastatin alone. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.
gov number, NCT01288469.)
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educing levels of low-density lipoprotein (LDL) cholesterol is a cornerstone of
the prevention of cardiovascular disease.1,2
European and U.S. guidelines recommend lowering
LDL cholesterol to less than 100 mg per deciliter
(2.6 mmol per liter) in persons with established
cardiovascular disease and to less than 70 mg per
deciliter (1.8 mmol per liter), or by 50% or more, in
those at highest risk.3,4
Statins are highly efficacious in lowering LDL
cholesterol. However, many patients, especially
those with very high initial LDL cholesterol levels
and those who have unacceptable side effects with
high-dose statins, do not reach recommended
target levels of LDL cholesterol.5,6 The addition
of bile-acid sequestrants, niacin, or ezetimibe to
statins produces an additional 10 to 20% reduction in LDL cholesterol,7 but there remains a
considerable unmet medical need for additional,
more effective therapeutic options that have acceptable side-effect profiles.
Serum proprotein convertase subtilisin/kexin
9 (PCSK9) binds to LDL receptors and promotes
their degradation, reducing the rate of removal of
LDL cholesterol from the circulation.8,9 Blocking
the interaction between PCSK9 and LDL receptors
with the use of REGN727/SAR236553 (designated
here as SAR236553), a fully human monoclonal
antibody that binds PCSK9, lowers LDL cholesterol levels in patients with hypercholesterolemia
— both those who are being treated with statins
and those who are not.10-12 The purpose of the
current study was to compare the effects of
SAR236553 coadministered with high-dose or lowdose atorvastatin, as compared with high-dose
atorvastatin alone, in patients with LDL cholesterol levels of 100 mg per deciliter or higher.
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proved by the institutional review board at each
participating institution. The academic authors had
full access to the data and drafted the manuscript.
The first and last authors made the decision to
submit the manuscript for publication, with approval of the sponsors. An employee of Publi
cation Planning Services provided writing and editorial support, funded by Sanofi and Regeneron
Pharmaceuticals. All the authors vouch for the accuracy and completeness of the data and the
analyses as presented and for the fidelity of
the study to the trial protocol, which is available
at NEJM.org.
Patients

Eligible patients included men and women 18 to
75 years of age with primary hypercholesterolemia
who had an LDL cholesterol level of 100 mg per
deciliter or higher at the end of the trial run-in
period (see below). Exclusion criteria were type 1
diabetes, type 2 diabetes treated with insulin or
poorly controlled (glycated hemoglobin level of
8.5% or higher), hepatic aminotransferase levels
that were more than twice the upper limit of the
normal range on repeat testing, triglyceride levels
higher than 350 mg per deciliter (3.95 mmol per
liter), or any cardiovascular or cerebrovascular event
or procedure within 6 months before the screening
visit. Women of childbearing potential were required to use suitable contraception throughout the
study. Concomitant therapy with statins other than
atorvastatin at the doses indicated in the protocol
or with other lipid-modifying drugs was not allowed during the study. Patients receiving thyroidreplacement therapy could be included if the dose
had been stable for at least 12 weeks before screening and if their serum thyrotropin level was within
10% of the normal range of the central laboratory.
All patients provided written informed consent.

Study Design and Oversight

Study Procedures

We conducted a phase 2, randomized, doubleblind, parallel-group, placebo-controlled study of
atorvastatin with or without SAR236553 at 20 sites
in the United States (see the Supplementary Appendix, available with the full text of this article
at NEJM.org, for a list of sites and investigators).
The trial was funded by Sanofi and Regeneron
Pharmaceuticals. Sanofi was responsible for the
design of the protocol, the collection and analysis
of the data, and monitoring of the study sites. The
trial protocol and patient consent form were ap-

Patients who had been on a stable regimen of
10 mg of atorvastatin for at least 6 weeks before
screening entered a 1-week run-in period, during
which therapy with 10 mg of atorvastatin was
continued. Patients who had not previously received atorvastatin or who had not been receiving
10 mg of atorvastatin for at least 6 weeks before
screening entered a 7-week run-in period, during
which they received open-label therapy with 10 mg
of atorvastatin. All patients were instructed regarding adherence throughout the study to a thera-
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munosorbent assays on microtiter plates coated
with a PCSK9 monoclonal antibody as the capture
reagent and a biotinylated mouse PCSK9 monoclonal antibody as the detection reagent. For the total
PCSK9 assay, soluble PCSK9 complexes, including
PCSK9:REGN727 complexes, were dissociated by
means of an acid-wash step.
Blood samples were obtained in the morning
under fasting conditions before injection of
SAR236553. All laboratory analyses were performed at Medpace Reference Laboratories as
described previously.10 LDL cholesterol levels were
calculated with the use of the Friedewald formula.13 HDL cholesterol was measured after precipitation of apolipoprotein B–containing lipoproteins
with dextran sulfate.14 We calculated non-HDL
cholesterol levels by subtracting HDL cholesterol
levels from total cholesterol levels. Levels of apolipoprotein A1, apolipoprotein B, and lipoprotein(a)
were measured by means of rate immunonephelometry (with the use of Dade Behring BN II
nephelometer, Siemens Healthcare Diagnostics) as
reported previously.10
Safety was assessed by means of clinical examination, reporting of adverse events, 12-lead
electrocardiography, measurement of vital signs,
and laboratory testing that included hematologic
tests, liver-function tests, and measurement of
creatine kinase levels. Anti-SAR236553 antibodies were assayed at baseline, week 4, and week
8, as well as at week 12 and week 16 (follow-up
Outcomes
visits). Data on adverse events were collected from
The primary efficacy outcome was the percent the time the patient signed the consent form until
change in calculated LDL cholesterol level from the the end of the study.
baseline level (which was the average of LDL cholesterol levels at week –1 and at randomization) to Statistical Analysis
week 8. Secondary efficacy outcomes included the Assuming that 5% of the patients would not be
absolute changes from baseline to week 8 in cal- able to be evaluated for the primary outcome, we
culated LDL cholesterol levels, total cholesterol lev- estimated that with 30 patients in each treatment
els, high-density lipoprotein (HDL) cholesterol lev- group, the study would have 95% power to detect a
els, triglyceride levels, non-HDL cholesterol levels, 20% difference in the primary outcome between
and the ratio of apolipoprotein B to apolipoprotein the patients assigned to 80 mg of atorvastatin plus
A1; the percent changes from baseline to week 8 in placebo and those assigned to 80 mg of atorva
levels of total cholesterol, HDL cholesterol, triglyc- statin plus SAR236553, with a standard deviation
erides, non-HDL cholesterol, apolipoprotein B, apo- of 20%, with the use of a two-sided t-test at the
lipoprotein A1, and lipoprotein(a); the proportions 0.05 significance level. The study was therefore deof patients achieving an LDL cholesterol level of signed to have 90 patients undergo randomization.
less than 100 mg per deciliter and less than 70 mg
Primary and secondary efficacy outcomes were
per deciliter at week 8; and the effects of SAR236553 analyzed in the modified intention-to-treat popuon fasting plasma glucose and glycated hemoglo- lation, which included all patients who underwent
bin levels. Free and total PCSK9 concentrations randomization and who had a primary end point
were measured by means of enzyme-linked im- that could be evaluated. An analysis of covariance
peutic lifestyle change (TLC) diet, as outlined in
the National Cholesterol Education Program Adult
Treatment Panel III guidelines.1
Patients who had an LDL cholesterol level of
100 mg per deciliter or higher during the run-in
period were randomly assigned, in a 1:1:1 ratio, to
receive 80 mg of atorvastatin daily plus SAR236553
once every 2 weeks, 10 mg of atorvastatin daily
plus SAR236553 once every 2 weeks, or 80 mg of
atorvastatin daily plus placebo once every 2 weeks.
Atorvastatin tablets of various doses (Pfizer) were
overencapsulated to look the same in order to
maintain blinding, and all patients took two capsules in the evening with dinner. In addition, either
SAR236553 or placebo was administered subcutaneously in the abdominal area every 2 weeks
from week 0 to week 6 (four treatments in total).
SAR236553 was expressed and purified at Regeneron Pharmaceuticals and supplied at a concentration of 150 mg per milliliter in 10 mM histidine,
pH 6.0, 0.2% polysorbate 20, and 10% sucrose. The
placebo was prepared with the use of the same
formulation. Patients were monitored at the investigational site for at least 30 minutes after each
study-drug injection.
After completion of the active treatment phase
(week 8), atorvastatin was no longer supplied as
part of the trial. Patients received their pretrial
therapy or no lipid-lowering treatment during the
follow-up period through week 16.
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(ANCOVA) model was used, with the treatment
group as the fixed effect and the corresponding
baseline lipid value as the covariate. The lastobservation-carried-forward method was used to
impute missing values at week 8 during the treatment period. For the ANCOVA model, the group
receiving 80 mg of atorvastatin plus SAR236553
was compared with the group receiving 80 mg of
atorvastatin plus placebo, and the 95% confidence
interval of the difference was calculated. For
secondary analyses or end points, P values have
been provided for descriptive purposes only and
have not been adjusted for multiple testing. Although formal comparisons with the group receiving 10 mg of atorvastatin plus SAR236553 were
not planned, they were performed post hoc for
descriptive purposes. The safety population comprised all patients who underwent randomization
and who received at least one dose or partial dose

of
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of SAR236553 or placebo. Safety outcomes were
described with the use of descriptive statistics.

R e sult s
Patients

The first patient entered the trial on January 11,
2011, and the last patient completed participation
on September 21, 2011. Of 214 patients screened,
92 met the entry criteria and had no conditions
that were specified as exclusion criteria; 30 patients were randomly assigned to 80 mg of ator
vastatin daily plus SAR236553 once every 2 weeks,
31 were assigned to 10 mg of atorvastatin daily
plus SAR236553 once every 2 weeks, and 31 were
assigned to 80 mg of atorvastatin daily plus placebo once every 2 weeks (Fig. S1 in the Supplementary Appendix). The baseline characteristics of
the patients are shown in Table 1.

Table 1. Baseline Characteristics of the Patients.*

Characteristic

Atorvastatin, 80 mg,
plus Placebo
(N = 31)

Atorvastatin, 10 mg,
plus SAR236553
(N = 31)

Atorvastatin, 80 mg,
plus SAR236553
(N = 30)

Total
(N = 92)

55.3±10.3

57.9±10.0

57.6±9.3

56.9±9.8

Demographic variables
Age
Mean — yr
≥65 yr — no. (%)

6 (19)

9 (29)

8 (27)

23 (25)

13 (42)

14 (45)

10 (33)

37 (40)

White

24 (77)

29 (94)

27 (90)

80 (87)

Black

7 (23)

2 (6)

3 (10)

12 (13)

29.8±4.4

29.4±5.1

29.3±4.0

29.5±4.5

Male sex — no. (%)
Race — no. (%)†

Cardiovascular history and risk factors
Body-mass index‡
Type 2 diabetes — no. (%)

7 (23)

4 (13)

3 (10)

14 (15)

15 (48)

17 (55)

15 (50)

47 (51)

Never smoked

17 (55)

17 (55)

20 (67)

54 (59)

Former smoker

7 (23)

10 (32)

7 (23)

24 (26)

Current smoker

7 (23)

4 (13)

3 (10)

14 (15)

Cerebrovascular disease — no. (%)

2 (6)

2 (6)

1 (3)

5 (5)

Coronary artery disease — no. (%)

0

2 (6)

1 (3)

3 (3)

Peripheral vascular disease — no. (%)

0

0

1 (3)

1 (1)

Hypertension — no. (%)
Smoking history — no. (%)

Cardiovascular medications — no. (%)
Agents acting on the RAS

5 (16)

13 (42)

9 (30)

27 (29)

Beta-blockers

2 (6)

7 (23)

5 (17)

14 (15)

Diuretics

4 (13)

3 (10)

7 (23)

14 (15)

Calcium-channel blockers

3 (10)

2 (6)

3 (10)

8 (9)
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Table 1. (Continued.)
Atorvastatin, 80 mg,
plus Placebo
(N = 31)

Characteristic

Atorvastatin, 10 mg,
plus SAR236553
(N = 31)

Atorvastatin, 80 mg,
plus SAR236553
(N = 30)

Total
(N = 92)

Lipid and lipoprotein levels — mg/dl
LDL cholesterol

121.2±18.1

119.7±15.5

126.9±21.8

122.6±18.7

Total cholesterol

200.8±26.3

199.2±20.4

210.3±29.8

203.4±25.9

HDL cholesterol

53.9±17.2

52.8±14.8

59.0±14.4

55.2±15.6

113.5

140.0

107.0

117.0

Triglycerides
Median
Interquartile range

87.0–145.0

Non-HDL cholesterol

146.9±23.5

146.4±19.0

93.0–169.0

151.3±26.3

79.0–159.0

148.2±22.9

84.8–158.0

Apolipoprotein B

100.4±16.3

103.9±16.0

107.0±19.5§

103.7±17.3

Apolipoprotein A1

153.8±35.3

158.7±29.1

165.6±30.9§

159.2±31.9

Lipoprotein(a)
Median
Interquartile range

18.0

23.0

27.0§

23.0

6.0–53.0

10.0–51.0

5.0–76.0

6.0–56.0

* Plus–minus values are means ±SD. There were no significant differences among the groups in any of the characteristics listed except with
respect to agents acting on the renin–angiotensin system (RAS), for which P = 0.049 for the comparison between 10 mg of atorvastatin plus
SAR236553 and 80 mg of atorvastatin plus placebo. Comparisons of means were performed with the use of Student’s t-test for parametric
variables and the Mann–Whitney test for nonparametric variables. Comparisons of percentages were performed with the use of Fisher’s exact test. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles
per liter, multiply by 0.01129. HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Data were missing for one patient.

Of the 92 patients in the trial, 80 (87%) completed the 8-week double-blind treatment period.
Four patients were not included in the modified
intention-to-treat analysis because no LDL cholesterol measurements were available after the initial baseline values were obtained. In addition,
no data on lipid levels were available from the
visit during the 8-week visit window (day 50 to
day 84) for 2 patients in the group that received
80 mg of atorvastatin plus SAR236553, 2 patients
in the group that received 10 mg of atorvastatin
plus SAR236553, and 5 patients in the group that
received 80 mg of atorvastatin plus placebo; data
from these patients were included in the analysis
with the use of the last-observation-carried-forward method.
Primary Outcome

After 8 weeks of treatment, the least-squares mean
(±SE) percent reduction in LDL cholesterol from
baseline was 73.2±3.5 with 80 mg of atorvastatin
plus SAR236553, as compared with 17.3±3.5 with
80 mg of atorvastatin plus placebo (least-squares
mean difference of −55.9±4.9 percentage points;
n engl j med 367;20

P<0.001). Because of a deviation from the assumption of a normal distribution and equality of variances required for ANCOVA testing, a sensitivity
analysis with the use of a rank-based ANCOVA
was performed and showed consistent results
(effect-size estimate of −54.5 percentage points;
P<0.001). The least-squares mean percent reduction
from baseline in LDL cholesterol after 8 weeks
with 10 mg of atorvastatin plus SAR236553 was
66.2±3.5. An analysis of the primary end point that
included only patients with data at week 8 (without imputation of missing data by means of the
last-observation-carried-forward method for patients who did not have data at week 8) yielded
similar results. When arithmetic means rather
than least-squares means were used in the calculations, the results were also similar (Table S1 in
the Supplementary Appendix).
Secondary Outcomes

All the patients in the two groups assigned to
SAR236553, as compared with 52% in the group
assigned to 80 mg of atorvastatin plus placebo,
achieved the target LDL cholesterol level of less
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than 100 mg per deciliter. A similar trend was
observed for the target LDL cholesterol level of less
than 70 mg per deciliter: 90% of the group that
received 80 mg of atorvastatin plus SAR236553
and 97% of the group that received 10 mg of atorvastatin plus SAR236553, as compared with 17%
of the group that received 80 mg of atorvastatin
plus placebo, met that target.
The percent changes from baseline to week 8 in
other lipid and apolipoprotein levels are shown
in Table 2. Absolute changes are shown in Tables
S2 and S3 in the Supplementary Appendix (calculated as both least-squares means and arithmetic
means for normally distributed values and as medians with interquartile ranges for values that were
not normally distributed). The changes in levels of
apolipoprotein B, non-HDL cholesterol, and total
cholesterol were similar to the changes in LDL
cholesterol. A modest increase in HDL cholesterol
was seen in patients treated with 80 mg of ator
vastatin plus SAR236553, as compared with those
treated with 80 mg of atorvastatin plus placebo.
No significant changes were seen in apolipoprotein A1 levels in any of the three trial groups.
Median lipoprotein(a) levels were substantially
reduced, by 31.0%, in patients receiving 80 mg
of atorvastatin plus SAR236553, as compared
with a reduction of 2.7% in the group receiving
80 mg of atorvastatin plus placebo.
The results of laboratory measurements of lipid
levels obtained at the week 12 and week 16 visits
(follow-up period) (Fig. 1) are consistent with
those that would be expected after the withdrawal of study-supplied lipid-lowering medications
after week 8. No notable changes were seen in
glycated hemoglobin or glucose levels in any of
the treatment groups (Table S4 in the Supplementary Appendix).
The changes in total and free serum PCSK9
concentrations are shown in Figure S2 in the Supplementary Appendix. A large increase in total
PCSK9 concentration was seen with the administration of SAR236553, owing to slower clearance
of the bound complex from the circulation (Fig.
S2A). In contrast, there was a marked reduction
in free PCSK9 concentration with SAR236553
(Fig. S2B).
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to 80 mg of atorvastatin (approximately 60%) and
were lower in the group assigned to 10 mg of
atorvastatin plus SAR236553 (45%). Five patients
prematurely discontinued study treatment owing
to an adverse event that occurred during treatment (four in the group that received 80 mg of
atorvastatin plus placebo and one in the group that
received 80 mg of atorvastatin plus SAR236553)
(Table 3). The patient who discontinued treatment
with 80 mg of atorvastatin plus SAR236553 reported a hypersensitivity reaction and rash, both
occurring 12 days after the second injection of
SAR236553. The rash was localized on both arms
and responded to treatment with an antihistamine.
There was one serious adverse event of dehydration in a patient who received 80 mg of atorvastatin plus SAR236553; the event was not thought
to be treatment-related. The patient recovered fully
after treatment with intravenous fluids. There
were no deaths. One patient in the group assigned to 80 mg of atorvastatin plus SAR236553,
who had had a mildly elevated aspartate aminotransferase level before undergoing randomization, had a transient increase in the aspartate
aminotransferase level to more than three times,
but less than five times, the upper limit of the
normal range (Table 3). Results regarding injection-site reactions are shown in Table S5 in the
Supplementary Appendix; 1 patient in the groups
assigned to SAR236553 therapy and 2 patients in
the group assigned to 80 mg of atorvastatin plus
placebo had an injection-site reaction. Antibodies against SAR236553 were detected at low titer
in 7 of the 56 patients in the SAR236533 groups
at week 8 (Table S6 in the Supplementary Appendix).

Discussion

In this phase 2 trial, the combination of 80 mg of
atorvastatin plus SAR236553 resulted in significantly greater reductions in LDL cholesterol levels than did 80 mg of atorvastatin plus placebo.
In addition, twice as many patients who received
80 mg of atorvastatin plus SAR236553 reached
the target LDL cholesterol levels of less than 100
mg per deciliter and more than five times as
many reached the target levels of less than 70 mg
Safety
per deciliter. No specific safety issues were idenOverall, the percentages of patients who reported tified, although larger studies will be necessary
at least one adverse event occurring during study to assess the potential risk of adverse effects of
treatment were similar in the two groups assigned SAR236553.
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−22.3 (−31.4 to −3.7) −58.3 (−63.9 to −50.2) −63.9 (−73.9 to −56.1)
−12.0 (−23.6 to −3.5) −54.4 (−60.2 to −48.3) −58.0 (−67.1 to −46.1)

Non-HDL cholesterol

Apolipoprotein B

<0.001

<0.001

<0.001

<0.001

0.03

0.37

0.005

<0.001

Atorvastatin, 80 mg,
plus SAR236553 vs.
Atorvastatin, 80 mg,
plus Placebo

<0.001

<0.001

<0.001

<0.001

0.84

0.09

0.06

<0.001

0.31

0.01

0.04

0.70

0.02

0.41

0.33

0.16

Atorvastatin, 10 mg, Atorvastatin, 80 mg,
plus SAR236553 vs. plus SAR236553 vs.
Atorvastatin, 80 mg, Atorvastatin, 10 mg,
plus Placebo
plus SAR236553

P Value†

* Plus–minus values are means ±SE. The modified intention-to-treat population included all patients who underwent randomization and who had a primary end point that could be evaluated. Since the assumptions of normal distribution and equality of variances were not verified for apolipoprotein B, non-HDL cholesterol, total cholesterol, lipoprotein(a) and triglycerides, values for these variables are expressed as median (interquartile range).
† The P value for the difference in the percent change in LDL cholesterol between 80 mg of atorvastatin plus SAR236553 and 80 mg of atorvastatin plus placebo was calculated with the
use of an analysis of covariance including terms for treatment and baseline value. No other P values have been adjusted for multiple comparisons and are included for descriptive purposes only.

−2.7 (−19.5 to 16.7) −34.7 (−50.0 to −24.7) −31.0 (−50.0 to −15.4)
−16.6 (−25.1 to −3.2) −40.5 (−44.8 to −36.0) −47.2 (−51.5 to −37.8)

−24.7 (−40.3 to −4.4)

Total cholesterol

−4.0 (−30.5 to 17.4)

−2.2±2.3

5.8±2.3

−73.2±3.5

Atorvastatin, 80 mg,
plus SAR236553

Lipoprotein(a)

−11.9 (−30.4 to 14.3)

Triglycerides

Median (interquartile range) percent change
from baseline to week 8

2.6±2.3
0.4±2.3

−3.6±2.3
−5.2±2.3

HDL cholesterol

Apolipoprotein A1

Atorvastatin, 10 mg,
plus SAR236553

−66.2±3.5

Atorvastatin, 80 mg,
plus Placebo

−17.3±3.5

LDL cholesterol

Mean least-squares percent change from
baseline to week 8

Outcome

Table 2. Efficacy Outcomes in the Modified Intention-to-Treat Population.*
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40

m e dic i n e

Atorvastatin, 80 mg, plus placebo
Atorvastatin, 10 mg, plus SAR236553
Atorvastatin, 80 mg, plus SAR236553

30

LDL Cholesterol
(mean percent change from baseline)

of

20
10
0
−10
−20
−30
−40
−50
−60
−70
−80

P<0.001
vs. Atorvastatin,
80 mg, plus
placebo

−90
−100

Baseline

2

4

6

8

12

16

8 LOCF

Week
No. of Patients
Atorvastatin, 80 mg, plus
placebo
Atorvastatin, 10 mg, plus
SAR236553
Atorvastatin, 80 mg, plus
SAR236553

29

29

27

25

24

25

21

29

29

29

26

26

27

27

24

29

30

29

28

28

28

27

27

30

Figure 1. Mean Percent Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol Levels, According to
Treatment Group.
Shown are the results for the primary efficacy outcome: the mean percent change from baseline in LDL cholesterol
levels to week 8, as calculated with the use of the last-observation-carried-forward (LOCF) method. Results are also
shown for the entire double-blind treatment phase (week 0 to week 8) and the follow-up period (week 8 to week 16).
All analyses were performed in the modified intention-to-treat population, which included all patients who underwent randomization and who had a primary end point that could be evaluated. The P value was calculated with the
use of an analysis of covariance including terms for treatment and baseline value. I bars indicate standard errors.

Although the results of this trial are pre
liminary, they suggest that administration of
SAR236553 with statins may benefit patients in
whom LDL cholesterol has not been reduced to
recommended levels, either because of an inadequate lipid-lowering response with high-dose
statins alone or because of unacceptable side effects with high-dose statins. The latter is a large
and growing problem in routine clinical practice,15 with few options other than statins currently available to clinicians to achieve substantial reductions in LDL cholesterol levels.
Although a comparison of various doses of
statins combined with SAR236553 was not the
intended focus of this trial, we did find that the
effects on the reduction of LDL cholesterol levels
of 80 mg of atorvastatin plus SAR236553 did not
differ significantly from the effects of 10 mg of
1898
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atorvastatin plus SAR236553. This finding suggests the possibility that there may be a limit to
the up-regulation of LDL-receptor activity. Our
study also supports previous observations that
suggested that the effects of inhibitors of PCSK9
on LDL cholesterol levels are not synergistic when
added to statins.
We found a consistent and fairly robust reduction of nearly one third in the median lipo
protein(a) level when SAR236553 was added to
either 80 mg of atorvastatin or 10 mg of ator
vastatin. This effect was first observed in the
phase 1 trials10 and has been confirmed as well
in two other phase 2 studies.11,12 Although the
mechanism underlying this effect is unknown,
one possible explanation is that with very low
levels of LDL-associated apolipoprotein B, the
apolipoprotein B component of lipoprotein(a)
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Table 3. Adverse Events and Potentially Clinically Significant Abnormalities in the Safety Population.*
Atorvastatin, 80 mg,
plus Placebo
(N = 31)

Event or Abnormality

Atorvastatin, 10 mg,
plus SAR236553
(N = 31)

Atorvastatin, 80 mg,
plus SAR236553
(N = 30)

number of patients (percent)
Adverse events occurring during study treatment
Any

19 (61)

14 (45)

18 (60)

Any serious

0

0

1 (3)

Resulting in death

0

0

0

Resulting in permanent discontinuation
of treatment

4 (13)

0

1 (3)

0

0

0

Potentially clinically significant abnormalities
Alanine aminotransferase >3× ULN
Aspartate aminotransferase >3× ULN

0

0

1 (3)

Total bilirubin >1.5× ULN

0

0

1 (3)

Creatine kinase >3× ULN

1 (3)

0

0

4 (13)

0

5 (17)

Dizziness

0

0

3 (10)

Headache

2 (6)

0

3 (10)

Any

7 (23)

4 (13)

3 (10)

Diarrhea

3 (10)

1 (3)

3 (10)

Adverse events occurring during study treatment
in ≥10% of patients in any treatment
group
Nervous system disorders

Gastrointestinal disorders

Musculoskeletal and connective-tissue
disorders
Any

6 (19)

2 (6)

5 (17)

Pain in extremity

5 (16)

0

1 (3)

* The safety population included all patients who underwent randomization and who received at least one dose or partial
dose of SAR236553 or placebo. Adverse events were classified according to the Medical Dictionary of Regulatory
Activities (MedDRA), version 14.0. ULN denotes the upper limit of the normal range.

becomes more accessible and is taken up by the
highly up-regulated LDL receptor. Alternatively,
low apolipoprotein B levels might contribute directly to a decrease in lipoprotein(a) synthesis.
The reductions in median triglyceride levels
were greater in the group assigned to 80 mg of
atorvastatin plus SAR236553 than in the group
assigned to 80 mg of atorvastatin plus placebo,
suggesting that the effect of atorvastatin on triglyceride levels may be enhanced slightly by
SAR236553. However, evaluation of these effects
was confounded by the relatively low baseline
triglyceride levels, and further studies involving
patients with hypertriglyceridemia are required
to fully investigate the effects of SAR236553 on
triglyceride-rich lipoproteins.

n engl j med 367;20

A small increase in HDL cholesterol levels
was observed in patients treated with 80 mg of
atorvastatin plus SAR236553 as compared with
those treated with 80 mg of atorvastatin plus
placebo. This finding is consistent with the
changes in HDL cholesterol levels seen in previous studies.13-15 Again, larger studies of longer
duration will be required to fully elucidate these
observations.
In conclusion, treatment with 80 mg of atorvastatin plus SAR236553 was associated with
significantly greater reductions in LDL cholesterol levels than was treatment with 80 mg of
atorvastatin plus placebo. Substantially more
patients who received SAR236553 than patients
who received placebo attained target LDL choles-

nejm.org

november 15, 2012

1899

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

An Antibody to PCSK9 for Hypercholesterolemia

terol levels of less than 100 mg per deciliter and
less than 70 mg per deciliter. The results of this
small study of short duration warrant further
investigation in large, longer-term studies.

Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
We thank Jackie Read, Ph.D., of Publication Planning Services
for providing writing and editorial support.
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